Skip to main content
Fig. 1 | Journal of Biomedical Science

Fig. 1

From: Dysregulation of SOX17/NRF2 axis confers chemoradiotherapy resistance and emerges as a novel therapeutic target in esophageal squamous cell carcinoma

Fig. 1

Expression signature analysis of endoscopic biopsy specimens from patients with different CCRT responses. A Volcano plot with annotated NRF2 downstream genes that were significantly upregulated in poor CCRT responders (n = 12) compared to good responders (n = 16). B Upregulation of NRF2 downstream genes in poor responders was further validated by using qRT-PCR analysis in 44 good plus 71 poor responders. C MTT assay of resistant and parental ESCC cells treated with various concentrations of cisplatin for 72 h. D Basal levels of NRF2 protein expression in the resistant and parental cells were examined by Western blot analysis. GAPDH was used as an internal control. E TCGA database analysis of expression of SOX17, NFE2L2, and NRF2-regulated genes in ESCC (n = 82). The statistics analysis compared NFE2L2 and NRF2-regulated genes to SOX17. F IHC staining showed an inverse correlation between SOX17 and NRF2 protein expression, and SOX17low/NRF2high was observed in poor responders. G and H Kaplan–Meier curves of overall (n = 164) (G) and progression-free (n = 101) (H) survival analysis based on the status of SOX17 and NRF2 expression in the nucleus. H: high expression; L: low expression. Data represents mean ± s.e.m. ns: non-significant; *p < 0.05; **p < 0.01; ***p < 0.001

Back to article page